Evidence map›Paper›PMID 24113858›Full record

ReviewJournal of medical toxicology : official journal of the American College of Medical Toxicology2013

The role of chelation in the treatment of other metal poisonings.

Silas W Smith

Abstract readReview
In one paragraph

Review in Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Article
  2. Chelation treatment in a novel sub-toxic multi-metal model in rats.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026
    Article
  3. Recent advances in therapeutic agents for uranium poisoning: a comprehensive review.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026
    Review
  4. Cobalt complexes in biology and medicine: enzymatic functions, pharmacological applications, and health challenges.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2026
    Review
  5. Review
  6. Review
  7. Pitfalls of serum aluminium testing.Occupational medicine (Oxford, England) · 2025
    Article
  8. Review
  9. Article
  10. Article
  11. Acta medica Philippina · 2024
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Silas W SmithDepartment of Emergency Medicine, Division of Medical Toxicology, New York University School of Medicine, New York, NY, USA, Silas.Smith@nyumc.org.

Funding

ENVIRONMENTAL HEALTH AND TOXICOLOGY: PROFESSIONAL EDUCATION AND PUBLIC HEALTH CONU61TS000117 · TS · AMERICAN COLLEGE OF MEDICAL TOXICOLOGY · PI KOSNETT, MICHAEL J · 2009 to 2013
$587k
ATSDR CDC HHS 1U61TS000117-04ATSDR CDC HHS U61 TS000117EAPO CDC HHS EP-HIT-13-001HSRD VA PEC 13-001
6 · The paper itself

Abstract

These proceedings will review the role of chelation in five metals-aluminum, cadmium, chromium, cobalt, and uranium-in order to illustrate various chelation concepts. The process of "chelation" can often be oversimplified, leading to incorrect assumptions and risking patient harm. For chelation to be effective, two critical assumptions must be fulfilled: the presumed "metal toxicity" must correlate with a given body or a particular compartment burden, and reducing this compartmental or the body burden (through chelation) attenuates toxicity. Fulfilling these assumptions requires an established dose-response relationship, a validated, reproducible means of toxicity assessment (clinical, biochemical, or radiographical), and an appropriate assessment mechanisms of body or compartment burden. While a metal might "technically" be capable of chelation (and readily demonstrable in urine or feces), this is an insufficient endpoint. Clinical relevance must be affirmed. Deferoxamine is an accepted chelator for appropriately documented aluminum toxicity. There is a very minimal treatment window in order to address chelation in cadmium toxicity. In acute toxicity, while no definitive chelation benefit is described, succimer (DMSA), diethylenetriaminepentaacetate (DTPA), and potentially ethylenediaminetetraacetic acid (EDTA) have been considered. In chronic toxicity, chelation is unsupported. There is little evidence to suggest that currently available chromium chelators are efficacious. Similarly, scant human evidence exists with which to provide recommendation for cobalt chelation. DTPA has been recommended for cobalt radionuclide chelation, although DMSA, EDTA, and N-acetylcysteine have also been suggested. DTPA is unsupported for uranium chelation. Sodium bicarbonate is currently recommended, although animal evidence is conflicting.

Indexed as

Chelation TherapyHeavy Metal PoisoningAluminumAnimalsBiomarkersBody BurdenChelating AgentsHumansMetals, HeavyPoisoningPredictive Value of TestsTreatment OutcomeAluminumBiomarkersChelating AgentsMetals, Heavy

Identifiers

PMID24113858
PMCPMC3846962

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.